Merck's Brinavess beats amiodarone in Phase III study
This article was originally published in Scrip
Executive Summary
Merck & Co/Cardiome Pharma's Brinavess (vernakalant) was superior to amiodarone injection for the conversion of heart rate from atrial fibrillation to sinus rhythm with 90 minutes of administration in the Phase III ARVO study, data show. The results were presented last week at Heart Rhythm 2010, the annual meeting of the Heart Rhythm Society.